Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus
- 1 October 1998
- Vol. 250 (2), 255-262
- https://doi.org/10.1006/viro.1998.9383
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsAntimicrobial Agents and Chemotherapy, 1997
- In Vitro Effect of α1‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease InhibitorsThe Journal of Infectious Diseases, 1997
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteinsAntimicrobial Agents and Chemotherapy, 1994
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988
- Pharmacokinetic effects of altered plasma protein binding of drugs in renal diseaseEuropean Journal of Drug Metabolism and Pharmacokinetics, 1984
- Penetration of Ampicillin and Dicloxacillin into Tissue Cage Fluid in Rabbits: Relation to Serum and Tissue Protein BindingScandinavian Journal of Infectious Diseases, 1981
- Protein Binding and Kinetics of Drugs in Liver DiseasesClinical Pharmacokinetics, 1977